Debio 1347

Drug Profile

Debio 1347

Alternative Names: CH 5183284; Debio1347; FF 284

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Debiopharm
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Signal transduction pathway inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer
  • Phase I Solid tumours

Most Recent Events

  • 14 Nov 2017 Debio 1347 receives Orphan Drug status for Biliary cancer in European Union
  • 10 Nov 2017 Phase-I/II clinical trials in Breast cancer (Combination therapy; Metastatic disease) in USA (PO) (NCT03344536)
  • 02 Jun 2017 Efficacy, adverse events, pharmacokinetics data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top